Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Preferred Stock Liabilities (2022 - 2023)

Serina Therapeutics (SER) has disclosed Preferred Stock Liabilities for 2 consecutive years, with $36.4 million as the latest value for Q4 2023.

  • Quarterly Preferred Stock Liabilities rose 36304.0% to $36.4 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $36.4 million through Dec 2023, up 36304.0% year-over-year, with the annual reading at $36.4 million for FY2023, 36304.0% up from the prior year.
  • Preferred Stock Liabilities hit $36.4 million in Q4 2023 for Serina Therapeutics, up from $14.8 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $36.4 million in Q4 2023 to a low of $100000.0 in Q4 2022.